New Solutions for Oncology

Tosk is on a mission to improve outcomes for cancer patients worldwide through the development of low-cost small molecule drugs designed to eliminate the adverse side effects associated with chemotherapeutics and radiation.

*For Accredited Investors Only

Contact to Invest
About Us

"We develop transformative, cost-effective therapies for cancer that will serve a worldwide market."

Hal Crow, Chairman

  • Clinical Stage, Small Molecule Drug Discovery, and Development Company​
  • Addressing Large, Unmet Medical Needs​, >50% of All Cancers​
  • Experienced Management Team​, Big Pharma​, Multiple Startup Exits​
  • $27 Million Funding to Date
Investor Brief
  • Reg D Offerings (Regulations Definitions)
  • Minimum Investment: $250,000
  • Company Raise: $10,000,000